Bone Biologics Corp - Common Stock (BBLG)
0.8013
+0.00 (0.00%)
NASDAQ · Last Trade: Jun 9th, 9:45 AM EDT
Detailed Quote
Previous Close | 0.8013 |
---|---|
Open | - |
Bid | 0.7800 |
Ask | 0.8000 |
Day's Range | N/A - N/A |
52 Week Range | 0.5700 - 4.250 |
Volume | 2,205 |
Market Cap | 2.62M |
PE Ratio (TTM) | -0.2990 |
EPS (TTM) | -2.7 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 353,929 |
Chart
About Bone Biologics Corp - Common Stock (BBLG)
Bone Biologics Corp is a biotechnology company focused on developing innovative solutions for the treatment of orthopedic conditions and bone-related injuries. The company is dedicated to advancing the field of bone healing through the creation of biologic products that promote bone regeneration and repair. By leveraging cutting-edge research and technology, they aim to address unmet medical needs in the orthopedic space, enhancing patient outcomes and improving recovery times. Their commitment to scientific advancement positions them at the forefront of bone healing therapies, contributing to the overall improvement of surgical procedures and rehabilitation practices in orthopedics. Read More
News & Press Releases

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced a planned reverse stock split of its shares of common stock at a ratio of 1-for-6. The reverse stock split will take effect as of 12:01 a.m. ET, on Tuesday, June 10, 2025, and shares of Bone Biologics are expected to trade on a post-split basis on Nasdaq under the existing trading symbol, “BBLG,” at the market open on June 10, 2025.
By Bone Biologics Corporation · Via Business Wire · June 6, 2025
Let's have a look at what is happening on the US markets after the closing bell on Thursday. Below you can find the top gainers and losers in today's after hours session.
Via Chartmill · April 3, 2025
Via Benzinga · April 3, 2025

Via Benzinga · October 29, 2024

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces the appointment of Phillip T. Meikle to the Company’s board of directors, effective immediately. Mr. Meikle succeeds Don R. Hankey, who retired from the Board following seven years of service. The number of directors of Bone Biologics remains at four.
By Bone Biologics · Via Business Wire · October 21, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 3, 2024

Via Benzinga · October 2, 2024

Via Benzinga · October 2, 2024

Via Benzinga · September 25, 2024

Via Benzinga · September 17, 2024

Via Benzinga · September 16, 2024

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that Jeffrey Frelick, chief executive officer, will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference being held September 9-11, 2024 in New York City. Bone Biologics’ company presentation will be available here beginning on Monday, September 9th at 7:00 a.m. Eastern time. The presentation will be available on the company’s website for a period of time here.
By Bone Biologics Corporation · Via Business Wire · September 4, 2024

BBLG stock results show that Bone Biologics beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 12, 2024

We have all of the biggest pre-market stock movers that traders need to know about on Friday with the latest news breakdowns!
Via InvestorPlace · August 9, 2024

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 781,251 shares of its common stock having an exercise price of $2.43 per share, originally issued in March 2024. The issuance of the shares of common stock issuable upon exercise of the existing warrants is registered pursuant to an effective registration statement on Form S-1 (File No. 333-276771).
By Bone Biologics Corporation · Via Business Wire · August 2, 2024

Via Benzinga · August 1, 2024

Via Benzinga · July 25, 2024

Via Benzinga · July 24, 2024

It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news to start the day with!
Via InvestorPlace · July 24, 2024

Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
By Virtual Investor Conferences · Via GlobeNewswire · June 21, 2024

Bone Biologics Corporation (“Bone Biologics” or the “Company”) (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, announces that the first two patients have been treated in the multicenter, prospective, randomized pilot clinical study of the Company’s NB1 bone graft device. NB1 is NELL-1 protein combined with demineralized bone matrix (DBM) to provide rapid, specific and guided control over bone regeneration.
By Bone Biologics Corporation · Via Business Wire · June 20, 2024

Via Benzinga · June 18, 2024